Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-07-17 Governance Information
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
独立董事制度
Governance Information Classification · 95% confidence The document is a detailed internal governance policy titled 'Independent Director System' issued by Beijing Xinghao Pharmaceutical Co., Ltd. It outlines the roles, responsibilities, nomination, election, and duties of independent directors, as well as the company's governance practices related to independent directors. It references relevant laws, regulations, and company bylaws. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and internal rules regarding independent directors, which fits the definition of Governance Information (CGR). The document length is substantial and contains detailed governance content, not a brief announcement or certification.
2025-07-17 Chinese
独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled as a work system for the independent directors' special meetings of Beijing Xinghao Pharmaceutical Co., Ltd. It details the governance rules, duties, meeting procedures, and responsibilities of independent directors. It references company law, securities exchange rules, and governance codes, but does not contain financial statements, earnings data, or audit results. It is a governance-related internal regulation document rather than a financial report or announcement. The document length is 3244 characters, which is relatively short and focused on governance rules. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-17 Chinese
国浩律师（上海）事务所关于北京星昊医药股份有限公司2023年股权激励计划调整事项之法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to a 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It contains detailed legal analysis, references to relevant laws and regulations, and descriptions of board and shareholder meetings approving the plan adjustments. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to corporate governance and management decisions. It is not a proxy solicitation or voting results announcement, but rather a legal advisory document concerning management and board matters. Therefore, the most appropriate classification is Board/Management Information (MANG), as it relates to management decisions and board approvals on equity incentive plans.
2025-07-17 Chinese
舆情管理制度
Governance Information Classification · 95% confidence The document is a detailed internal policy titled '舆情管理制度' (Public Opinion Management System) issued by the company's board. It outlines the company's procedures and responsibilities for managing public opinion and media crises, including organizational structure, reporting, and response measures. There is no financial data, no mention of financial results, no shareholder voting results, no legal proceedings, no capital changes, no earnings information, and no regulatory filings or announcements. It is a governance-related document describing internal rules and management practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length (4043 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive governance policy document.
2025-07-17 Chinese
关联交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for related party transactions of Beijing Xinghao Pharmaceutical Co., Ltd. It details internal control policies, definitions of related parties, procedures for approval and voting, and other governance aspects related to related party transactions. There is no financial data, earnings information, or audit results presented. The document is a detailed governance policy rather than a report or announcement of financial results or corporate actions. It is not a report publication announcement since it contains substantive content rather than a brief notice. The content fits best under Governance Information (CGR) as it outlines internal rules and governance practices related to related party transactions.
2025-07-17 Chinese
监事会关于调整2023年股权激励计划相关事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a supervisory board opinion on adjustments related to the 2023 equity incentive plan of Beijing Xinghao Pharmaceutical Co., Ltd. It references legal and regulatory frameworks, the company's articles of association, and the equity incentive plan draft. The document discusses the adjustment of repurchase prices and exercise prices following the implementation of the 2024 annual equity distribution (dividend). The document is a formal announcement of the supervisory board's verification and approval of these adjustments. It does not contain full financial statements or detailed financial performance data, nor is it a report like an annual or interim report. It is not a call transcript, earnings release, or management report. It is not a report publication announcement but a regulatory announcement related to equity incentive plan adjustments. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other categories.
2025-07-17 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.